Statin Adjunct Therapy - Zetia, Revenue Protection for Zocor?

Overview

Introduction

Scope

Report Highlights

Reasons to Purchase

DRIVERS AND TRENDS

Recent research suggests that around six out of ten patients with CHD receiving statin therapy were not at their LDL cholesterol target, as recommended by the NIH. This brief analyses the uptake of adjunctive therapies to statins, focusing on the future role of Zetia (ezetimibe) as an add-on therapy and as a single pill combination therapy with the first generation statin Zocor (simvastatin).

PATIENT POTENTIAL

Definition and segmentation of dyslipidemia combined with epidemiology data including:

• Estimated prevalence of hypercholesterolemia in the seven major markets from 2002 to 2010
• Prevalence of low HDL cholesterol broken down by age in the UK as an indicator of global trends

UPTAKE OF ADJUNCTIVE

Profiles of three existing adjunctive anti-dyslipidemics therapies, Niaspan, Advicor, and WelChol evaluating their patient and market potential.

• Drug Overview
• Clinical trial data
• Commercial potential

POTENTIAL FOR ZETIA

Examination of the commercial potential of Merck & Co./Schering-Plough' s cholesterol absorption inhibitor Zetia

• The historical development of the drug
• Existing clinical trial data for the use of the drug as a monotherapy and in combination with statins
• The potential drivers of Zetia' s commercial success, assessing the future role of the drug in the treatment of dyslipidemia
• Possible barriers to Zetia' s uptake

DATASETS

Table 1: Prevalence of hypercholesterolemia in the seven major markets (000s), 2002-2010

Table 2: Estimated prevalence of low HDL cholesterol (<40mg/dL) in the UK, 2003

Table 3: Cost comparison of Advicor single-pill combination versus Niaspan and generic lovastatin components

Table 4: Efficacy of Welchol as a monotherapy and in combination in reducing LDL cholesterol and triglyceride levels, and in increasing HDL cholesterol

Table 5: Clinical trial results for the use of Zetia as a monotherapy

Table 6: Clinical trial results obtained when adding ezetimibe to ongoing statin therapy in patients who had not met LDL cholesterol targets

Table 7: Clinical trial results obtained with the concurrent initiation of ezetimibe and statin therapy

Table 8: Comparison of Niaspan, Advicor and WeChol

Table 9: Factors that may drive of limit the uptake and potential of Zetia

Table 10: Number of fatal cases of rhabdomyolysis linked to statin usage in the US in 2001

Table 11: Key changes to lipid levels between the NCEP II and NCEP III

Table 12: Phase III trial results comparing rosuvastatin with atorvastatin

Table 13: Costs of statin monotherapy compared to Zetia/statin combination therapy

Table 14: Forecast sales of Zetia from 2003 to 2008 ($m)

Figure 1: Key factors in the market dynamics of Niaspan

Figure 2: Advicor: SWOT analysis

Figure 3: Key factors in the market dynamics of WelChol